Market Cap 163.51B
Revenue (ttm) 29.44B
Net Income (ttm) 8.51B
EPS (ttm) N/A
PE Ratio 15.54
Forward PE N/A
Profit Margin 28.90%
Debt to Equity Ratio 0.95
Volume 7,923,800
Avg Vol 7,911,278
Day's Range N/A - N/A
Shares Out 1.24B
Stochastic %K 86%
Beta 0.32
Analysts Strong Sell
Price Target $158.72

Company Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 650 574 3000
Fax: 650 522 5853
Address:
333 Lakeside Drive, Foster City, United States
AcceleratorModel
AcceleratorModel Jul. 16 at 8:38 PM
$GILD made HOD near end of session 2nd day in a row :)
0 · Reply
DefenseMania
DefenseMania Jul. 16 at 8:30 PM
$ABBV $AMGN $MO $VZ $GILD DANG !!! just a few of my dividend income stocks on 🔥 the compounding is INSANE !!!!!!!!!!
0 · Reply
Sirtuan
Sirtuan Jul. 16 at 6:46 PM
$ABT $GILD $ISRG pharma starting to look nice.
0 · Reply
AcceleratorModel
AcceleratorModel Jul. 16 at 5:24 PM
$GILD it’s working …
0 · Reply
Wigglyick
Wigglyick Jul. 16 at 4:05 PM
$GILD looking constructive , give it some time/space
0 · Reply
Biotech_Beast
Biotech_Beast Jul. 16 at 1:28 PM
$VIR (I'm long). Has multiple catalysts ahead in hepatitis delta and oncology. There is competition in Hep delta from $MIRM and $GILD although it looks beatable, in my opinion, and the Astellas partnership shows the potential value of the oncology pipeline. https://seekingalpha.com/article/4922611-vir-biotechnology-stock-multiple-catalysts-hepatitis-oncology-ahead
0 · Reply
topstockalerts
topstockalerts Jul. 16 at 12:52 PM
Kalshi launched 13 new prediction market contracts tied to biotechnology clinical trial outcomes and regulatory decisions, expanding its event-based trading offerings. Developed in partnership with AI intelligence firm AppliedXL, the contracts allow traders to speculate on whether the FDA will approve drugs from companies including Sanofi and Gilead Sciences. The new products are designed to isolate binary events such as drug approvals from broader stock price performance, providing investors with a way to trade regulatory outcomes directly rather than taking exposure to an entire company's shares. According to Bloomberg, Kalshi is also exploring additional prediction markets tied to real-world events, including flight cancellation rates at specific airports, highlighting the platform's continued expansion beyond politics and macroeconomic events. $SNY $GILD
0 · Reply
KenFaulkenberry
KenFaulkenberry Jul. 15 at 11:23 PM
$GILD Gilead Sciences (GILD) Stock Analysis Gilead offers a mix of dependable cash flow from its HIV treatments and upside potential from its growing oncology pipeline. The stock provides an attractive dividend yield, rare for the biotech sector, making it appealing to income-focused investors. For those seeking exposure to a financially strong biotech firm with room to grow. Is the stock price a Buy, Sell, or Hold? What is the Intrinsic Value of Gilead Sciences (GILD)? https://dividendvaluebuilder.com/gilead-sciences-gild-dividend-stock-analysis/
0 · Reply
JFDI
JFDI Jul. 15 at 7:22 PM
1 · Reply
AcceleratorModel
AcceleratorModel Jul. 14 at 4:17 PM
$GILD tap the 20 and go already !
0 · Reply
Latest News on GILD
Gilead price target lowered to $156 from $157 at Truist

2026-07-07T13:16:30.000Z - 10 days ago

Gilead price target lowered to $156 from $157 at Truist


Gilead price target lowered to $120 from $122 at RBC Capital

2026-07-07T11:26:01.000Z - 10 days ago

Gilead price target lowered to $120 from $122 at RBC Capital


Gilead upgraded to Buy from Hold at HSBC

2026-07-06T09:45:12.000Z - 11 days ago

Gilead upgraded to Buy from Hold at HSBC


FDA approves Gilead’s Trodelvy for two indications

2026-06-24T19:10:51.000Z - 22 days ago

FDA approves Gilead’s Trodelvy for two indications

MRK


The Healthcare M&A Wave

Jun 17, 2026, 12:30 PM EDT - 4 weeks ago

The Healthcare M&A Wave

ABT ALNY AMGN AMRX ANTX AZN BDX


Gilead announces FDA approval of sNDA for Yeztugo

2026-06-15T20:41:58.000Z - 4 weeks ago

Gilead announces FDA approval of sNDA for Yeztugo


US FDA approves Gilead's drug for deadly liver infection

May 22, 2026, 2:06 PM EDT - 7 weeks ago

US FDA approves Gilead's drug for deadly liver infection


Gilead Prices $3 Billion of Senior Unsecured Notes

May 14, 2026, 9:21 PM EDT - 2 months ago

Gilead Prices $3 Billion of Senior Unsecured Notes


Gilead Sciences Expects Loss This Year on Acquired R&D Expenses

May 7, 2026, 4:39 PM EDT - 2 months ago

Gilead Sciences Expects Loss This Year on Acquired R&D Expenses


Gilead Sciences Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Gilead Sciences Earnings Call Transcript: Q1 2026


Gilead Sciences Slides: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Gilead Sciences Slides: Q1 2026


Gilead Sciences Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Gilead Sciences Earnings release: Q1 2026


Gilead Sciences Quarterly report: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Gilead Sciences Quarterly report: Q1 2026


Gilead Sciences Announces First Quarter Financial Results

May 7, 2026, 4:01 PM EDT - 2 months ago

Gilead Sciences Announces First Quarter Financial Results


Gilead Sciences Slides: Investor presentation

May 7, 2026, 7:00 AM EDT - 2 months ago

Gilead Sciences Slides: Investor presentation


Can You Sue A Drug Company For Not Inventing Faster?

May 4, 2026, 5:15 AM EDT - 2 months ago

Can You Sue A Drug Company For Not Inventing Faster?


Gilead Sciences Transcript: AGM 2026

Apr 30, 2026, 1:00 PM EDT - 2 months ago

Gilead Sciences Transcript: AGM 2026


Protests: AHF Blasts Gilead Over Extortionate AIDS Drug Pricing

Apr 13, 2026, 9:57 PM EDT - 3 months ago

Protests: AHF Blasts Gilead Over Extortionate AIDS Drug Pricing


AHF Slams Gilead for Role in Florida AIDS Drug Crisis

Apr 10, 2026, 1:01 PM EDT - 3 months ago

AHF Slams Gilead for Role in Florida AIDS Drug Crisis


Gilead Sciences Transcript: M&A announcement

Apr 7, 2026, 4:30 PM EDT - 3 months ago

Gilead Sciences Transcript: M&A announcement


Gilead Sciences Press release: M&A announcement

Apr 7, 2026, 4:30 PM EDT - 3 months ago

Gilead Sciences Press release: M&A announcement


Gilead Sciences Slides: M&A announcement

Apr 7, 2026, 4:30 PM EDT - 3 months ago

Gilead Sciences Slides: M&A announcement


Gilead to acquire Tubulis GmbH for up to $5 billion

Apr 7, 2026, 8:23 AM EDT - 3 months ago

Gilead to acquire Tubulis GmbH for up to $5 billion


Gilead Extends Tender Offer to Acquire Arcellx

Apr 1, 2026, 4:13 PM EDT - 3 months ago

Gilead Extends Tender Offer to Acquire Arcellx


Markets Haven't Changed. These 2 Cheap Dividends Still Rule

Apr 1, 2026, 10:50 AM EDT - 3 months ago

Markets Haven't Changed. These 2 Cheap Dividends Still Rule

WM


AcceleratorModel
AcceleratorModel Jul. 16 at 8:38 PM
$GILD made HOD near end of session 2nd day in a row :)
0 · Reply
DefenseMania
DefenseMania Jul. 16 at 8:30 PM
$ABBV $AMGN $MO $VZ $GILD DANG !!! just a few of my dividend income stocks on 🔥 the compounding is INSANE !!!!!!!!!!
0 · Reply
Sirtuan
Sirtuan Jul. 16 at 6:46 PM
$ABT $GILD $ISRG pharma starting to look nice.
0 · Reply
AcceleratorModel
AcceleratorModel Jul. 16 at 5:24 PM
$GILD it’s working …
0 · Reply
Wigglyick
Wigglyick Jul. 16 at 4:05 PM
$GILD looking constructive , give it some time/space
0 · Reply
Biotech_Beast
Biotech_Beast Jul. 16 at 1:28 PM
$VIR (I'm long). Has multiple catalysts ahead in hepatitis delta and oncology. There is competition in Hep delta from $MIRM and $GILD although it looks beatable, in my opinion, and the Astellas partnership shows the potential value of the oncology pipeline. https://seekingalpha.com/article/4922611-vir-biotechnology-stock-multiple-catalysts-hepatitis-oncology-ahead
0 · Reply
topstockalerts
topstockalerts Jul. 16 at 12:52 PM
Kalshi launched 13 new prediction market contracts tied to biotechnology clinical trial outcomes and regulatory decisions, expanding its event-based trading offerings. Developed in partnership with AI intelligence firm AppliedXL, the contracts allow traders to speculate on whether the FDA will approve drugs from companies including Sanofi and Gilead Sciences. The new products are designed to isolate binary events such as drug approvals from broader stock price performance, providing investors with a way to trade regulatory outcomes directly rather than taking exposure to an entire company's shares. According to Bloomberg, Kalshi is also exploring additional prediction markets tied to real-world events, including flight cancellation rates at specific airports, highlighting the platform's continued expansion beyond politics and macroeconomic events. $SNY $GILD
0 · Reply
KenFaulkenberry
KenFaulkenberry Jul. 15 at 11:23 PM
$GILD Gilead Sciences (GILD) Stock Analysis Gilead offers a mix of dependable cash flow from its HIV treatments and upside potential from its growing oncology pipeline. The stock provides an attractive dividend yield, rare for the biotech sector, making it appealing to income-focused investors. For those seeking exposure to a financially strong biotech firm with room to grow. Is the stock price a Buy, Sell, or Hold? What is the Intrinsic Value of Gilead Sciences (GILD)? https://dividendvaluebuilder.com/gilead-sciences-gild-dividend-stock-analysis/
0 · Reply
JFDI
JFDI Jul. 15 at 7:22 PM
1 · Reply
AcceleratorModel
AcceleratorModel Jul. 14 at 4:17 PM
$GILD tap the 20 and go already !
0 · Reply
dogDazeSummer
dogDazeSummer Jul. 14 at 1:57 PM
$IFRX Welcome Fidelity Sector Fund. The first real mutual fund for our German baby in a long time. Now w funding risk removed in “shoe in for AAV” (given Amgen sketchiness. EMA / FDA clearly seek retribution). And the first major Biotech *mutual fund* takes a 3.2m share starter. Follow the leaders. This Fidelity fund holds about 114 positions Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund 3.2M shares Inflarx. May 31, 2026 4.42% 6,392,142 26 year old fund FY July, +22% YTD; +77% TTM; 10% over 10 years. 159 Holdings Inflarx is now just 1 of 6 international holdings. Obviously a special situation and wisely bought on pullbacks 5 Star Mormingside Fund in all categories Profile: Eirene Kontopoulos Since 07/14/2018 B.S., Haverford College, 2002 PhD, Harvard University - Harvard Medical School, 2007 Top Holdings: $ABBV $GILD $BIIB $ALNY https://institutional.fidelity.com/app/funds-and-products/116/fidelity-advisor-biotechnology-fund-class-i-fbtix.html
1 · Reply
ETAlpha
ETAlpha Jul. 13 at 3:44 PM
$AGEN Falling wedge Needs close back above wedge (7-7.1) Big level here at VWAP 5 minute close needed over wedge for entries IMO otherwise NO ENTRY For more action in the biotech and immuno-oncology space, keep an eye on related tickers $CRBU (Caribou Biosciences) and $GILD (Gilead Sciences). Price always speaks first. I'll post the chart when the signal is confirmed. Check out my homepage for more information!
0 · Reply
SilverEagle
SilverEagle Jul. 13 at 1:39 PM
$GILD false B/O or retest?
0 · Reply
BioTechHealthX
BioTechHealthX Jul. 12 at 12:26 AM
$GILD Gilead Sciences Inc. (NASDAQ: GILD) built its reputation in antiviral medicine, but its biggest opportunity may be in cancer immunotherapy and cell therapy. Discover why investors believe this biotech stock could be one of the market's most overlooked long-term healthcare winners. https://biotechhealthx.com/biotech-news/is-gilead-sciences-gild-still-a-smart-healthcare-stock-to-buy/
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 11 at 9:33 PM
$SLS published SLS009 Ph2 AML-MR trial data at ASH is better than Magrolimab P1B AML-MR data that $GILD bought for $4.9B - just the secondary asset is right now worth - $25 per share - right now.
0 · Reply
Quantumup
Quantumup Jul. 10 at 6:14 PM
H.C. Wainwright (a/o 7/7) reit'd $ALGS Buy-$50 after hosting ALGS for a fireside chat. $GILD $ABUS ASMB GSK - IONS RHHBY VIR JNJ MDGL IVA VKTX LGND NVO Here's what H.C. Wainwright said in its note: https://x.com/Quantumup1/status/2075644271281975530?s=20
0 · Reply
AcceleratorModel
AcceleratorModel Jul. 9 at 7:49 PM
$GILD in 134
0 · Reply
2kmagnix2k
2kmagnix2k Jul. 9 at 5:24 PM
$GILD Come on! Lets go!
0 · Reply
Synaptric
Synaptric Jul. 9 at 1:09 PM
Biotechs with interesting price-sentiment divergence. Sentiment falling even though price momentum rising or flat $OCGN $AMGN $GILD $VRTX Will sentiment lead price or will price lead sentiment??? $XBI
1 · Reply
AdamBrennan2
AdamBrennan2 Jul. 9 at 2:37 AM
$REGN Regeneron is down about 45% Its now very attractive vs other biotech stocks wheen looking at lowest valuation with its highest expected growth.. anyone bought this? $EXEL $GILD $INSM $NBIX
0 · Reply
Jxcx1990
Jxcx1990 Jul. 7 at 8:29 PM
$GILD trade idea https://x.com/altjxcx1990/status/2074589859340046547?s=46
0 · Reply
JFDI
JFDI Jul. 7 at 3:57 PM
$GILD another B/O after slow grind into the 200d
0 · Reply